CClinicalTrials.gg
Status unknownNCT01327807CCIRUpdated Mar 12, 2014

Cure Cystinosis International Registry

An observational study in Cystinosis, Nephropathic Cystinosis and Renal Fanconi Syndrome, sponsored by Cystinosis Research Foundation. Status unknown at 1 site in United States. Per ClinicalTrials.gov, last updated 2014-03-12.

Sponsored by Cystinosis Research Foundation · Observational

The sponsor has not verified this record recently (last verified Mar 2014), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Time perspective
Cross-sectional
Enrollment
750
Sex
All
01

Study summary

Cure Cystinosis International Registry (CCIR) is an online, patient self-identifying registry developed by medical and scientific experts specifically for the cystinosis community.

CCIR's sole purpose is to identify people with cystinosis worldwide in an effort to accelerate novel treatments and a cure for cystinosis.

CCIR provides a safe and secure platform for:

  • sharing anonymous medical information about cystinosis with researchers, clinicians and patients
  • disseminating information about research opportunities
  • connecting researchers/investigators and prospective participants *

Interested cystinosis patients may register themselves with CCIR online at http://www.cystinosisregistry.org.

* No personal information is shared outside of CCIR. Individual identities are known only to appropriate CCIR staff. If a participant is matched to a clinical trial, the participant receives a notice from CCIR, after which they can decide whether they wish to contact the study sponsor.

Read the detailed description

Significance and Purpose:

Many different resources and tools are necessary to make significant advances in medical research. Progress in rare diseases such as cystinosis can often be impeded by the lack of information available about the disease and limited access to volunteers eligible for clinical trials. Therefore, patients who are willing to provide information about how the disease has affected them and also make themselves available to participate in trials are among the most valuable resources the investigators have to fight a disease. However, the research community desperately needs the right tool that will permit access to these resources.

A tool widely used to conveniently collect both data about a disease and information about potential clinical trial participants is a patient registry. A patient registry is any system that allows for the organized collection of data about disease outcomes in affected populations for a scientific, clinical, or policy purpose. The Cystinosis Research Foundation (CRF) has aligned itself with cystinosis medical experts and organizations worldwide to create the first ever international, online patient registry for cystinosis, Cure Cystinosis International Registry (CCIR). The express purpose of CCIR is to make anonymous information available to the research community and thus promote accelerated research in advanced treatments and ultimately a cure for cystinosis.

Objectives:

The objectives of CCIR are:

  • Evaluate epidemiology and clinical characteristics of cystinosis around the world.
  • Evaluate and compare the diagnosis, treatment, and kidney transplant rates among cystinosis communities from different geographical areas.
  • Enhance the understanding of how cystinosis affects quality of life.

CCIR Registration:

Interested cystinosis patients may register themselves with CCIR online at http://www.cystinosisregistry.org. Registration is easy and secure. Simply go to the website and create a CCIR account and complete a survey. The CCIR website is currently available in English and Spanish, and will soon be available in French, Portuguese, and possibly other languages.

Benefits to CCIR participants include instant access to the registry's accumulated survey results (reported as anonymous group data), and opportunities to submit questions to cystinosis experts and to learn of clinical trial opportunities. No personal information is shared outside of CCIR. Individual identities are known only to appropriate CCIR staff.

02

Conditions studied

  • Cystinosis
  • Nephropathic Cystinosis
  • Renal Fanconi Syndrome

Keywords

  • Registries
  • Cystinosis
  • Nephropathic Cystinosis
  • Renal Fanconi Syndrome
  • Cystine
  • Kidney
  • Rare Diseases
03

In context

Fanconi Syndrome

72 studies on the registry are indexed under Fanconi Syndrome; 11 are open to participants now.

This study's planned enrollment of 750 is above the median of 53 across 20 observational studies indexed under Fanconi Syndrome.

Browse Fanconi Syndrome studies →

Lead sponsor

This is the only study on the registry with Cystinosis Research Foundation as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

International cystinosis community

Eligibility criteria

Inclusion Criteria:

  • Diagnosis of cystinosis
05

Study design

Time perspective
Cross-sectional
Enrollment
750 participants (estimated)

Groups and cohorts

  • Cystinsosis patients

    Those with a diagnosis of cystinosis.

06

What researchers measure

Primary outcomes

  1. Age at treatment initiation and the effect on disease outcomes

    Time frame: Lifetime

07

Study locations

1 of 1 sites recruiting
  • University of California, San Diego
    San Diego, California 92103-8450, United States
    Recruiting
08

References and documents

Publications

  • Cherqui S. Cysteamine therapy: a treatment for cystinosis, not a cure. Kidney Int. 2012 Jan;81(2):127-9. doi: 10.1038/ki.2011.301. PubMed 22205430 ↗
  • Gangoiti JA, Fidler M, Cabrera BL, Schneider JA, Barshop BA, Dohil R. Pharmacokinetics of enteric-coated cysteamine bitartrate in healthy adults: a pilot study. Br J Clin Pharmacol. 2010 Sep;70(3):376-82. doi: 10.1111/j.1365-2125.2010.03721.x. PubMed 20716238 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 12, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01327807
Lead sponsor
Cystinosis Research Foundation
Responsible party
Jerry A. Schneider (Professor Emeritus of Pediatrics, Cystinosis Research Foundation) — Principal investigator
First posted
Apr 4, 2011
Start date
Aug 2010
Primary completion
Dec 2020 (estimated)
Completion
Dec 2022 (estimated)
Last update
Mar 12, 2014

Study contacts

Betty L Cabrera, M.P.H
Contact
curator@cystinosisregistry.org
858-822-3747
Jerry A Schneider, M.D.
principal investigator · University of California, San Diego

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion